Bluejay Diagnostics completes commercial-scale IL-6 antibody production for Symphony cartridges

Bluejay Diagnostics, Inc.

Completed commercial-scale production of polyclonal and monoclonal anti-IL-6 antibodies meeting internal performance criteria.
Antibodies intended for Symphony cartridge manufacturing for clinical and potential future commercial applications.
Sufficient material to support production of over 9 million Symphony cartridges; additional capacity established.
Symphony System remains under development, subject to further validation and FDA clearance before marketing.
Monoclonal antibodies designated as detection antibodies showed acceptable binding, specificity, and signal performance.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.